Stores samples from people with sickle cell to study kidney disease
Collects blood and urine from people with sickle cell to study kidney disease.
Key facts
- Who runs it
- University of Texas Southwestern Medical Center
- Where
- Dallas, United StatesSee the 2 sites
- Trial code
- Registry title
- Sickle Cell Kidney Biorepository
- Status
- Recruiting
- People taking part
- 800 people, planned
- Started
- 22 Aug 2024
- Expected to end
- Dec 2049
- Type of study
- Observational
- Record updated
- 13 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 65 who have sickle cell disease or sickle cell trait, or another hemoglobin disorder, to give blood and urine samples for kidney research. Some people without a hemoglobin disorder can join as controls.
- Age
- 18 to 65 years.
- Sex
- All sexes can join.
- Disease stage
- Any hemoglobin disorder, such as sickle cell disease or sickle cell trait, confirmed by hemoglobin electrophoresis or genetic testing. Kidney function (eGFR) must be 15 mL/min or higher.
- Earlier treatment
- People on dialysis cannot join. People on induction or consolidation cancer treatment cannot join. Maintenance chemotherapy in remission will be considered.
- Biomarker or test result
- A hemoglobin disorder confirmed by hemoglobin electrophoresis or genetic testing. Controls have no hemoglobin disorder.
Main reasons for not taking part
- Age 66 years or older
- Kidney function (eGFR) below 15 mL/min, or on dialysis
- Active pregnancy (can join 4 weeks or more after delivery)
- Active sickle cell pain episode needing hospital, emergency room or pain clinic care (can join 2 weeks or more after the pain has resolved)
- Active cancer on induction or consolidation treatment
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Age over 18 years,
- Estimated glomerular filtration rate greater than or equal to 15 mL/min,
- Presence of any hemoglobinopathy (will need to be confirmed by hemoglobin electrophoresis or genetic testing),
- Controls (absence of hemoglobinopathy) will be subject to review and only selected if demographics are identical to a currently enrolled participant with a hemoglobinopathy
Who cannot take part
- Active malignancy on induction or consolidation treatment. Maintenance chemotherapy in remission will be considered,
- Age 66 years or older,
- Estimated glomerular filtration rate less than 15 mL/min or on dialysis,
- Active pregnancy (may be enrolled 4 weeks or more after delivery),
- Active sickle cell pain episode requiring hospitalization or emergency room visit or pain infusion clinic visit (may be enrolled 2 weeks or more after resolution of severe pain),
- Prisoners
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in United States
- Parkland Memorial HospitalDallas, United StatesContact: Kabir O Olaniran, MD, MPH, FASNTaking people
- University of Texas Southwestern Medical CenterDallas, United StatesContact: Kidney Clinical Research OfficeTaking people
About the trial
What the trial wants to find out
Kidney disease is a major cause of illness and death in people with sickle cell disease and sickle cell trait. Despite these concerning facts, we do not (1) have an in-depth understanding of how kidney disease starts in sickle cell disease and sickle cell trait, (2) have detailed insights into why kidney disease is worse in people with sickle cell disease and sickle cell trait, (3) have management options that are tailored to treating or preventing kidney disease in people with sickle cell disease or sickle cell trait.
Read full original descriptionShow less
The SCeK Biorepository is a specialized, secure repository designed for the collection of blood and urine samples from people with sickle cell disease and sickle cell trait. These samples are connected to detailed medical records, with the sole purpose of allowing researchers to better understand how kidney disease starts and progresses in people with the sickle cell gene. By studying these stored samples (using new tests) together with health information, researchers can find better early warning signs of kidney injury and develop better ways to protect kidney health in people with sickle cell disease and sickle cell trait.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Sickle Cell Kidney (SCeK) Biorepository
- Plain-language title
- Stores samples from people with sickle cell to study kidney diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07064174, who can take part
- Record updated
- 13 April 2026